ArticleCirculation. Heart failure2019
Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure.
Article in Circulation. Heart failure, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02556450 (Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure. A Proof of Concept Clinical Trial Within the EU FP 7), which is not on this map. Cited by 50 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure. A Proof of Concept Clinical Trial Within the EU FP 7 (European Union FP7) "HOMAGE" Programme " Heart OMics in AGing "
Who cites it
50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- Development and Validation of a Protein Risk Score for Mortality in Heart Failure : A Community Cohort Study.Annals of internal medicine · 2024Pooled it
- Protein biomarkers of cardiac remodeling and inflammation associated with HFpEF and incident events.Scientific reports · 2022Pooled it
- Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization.Circulation · 2022Pooled it
- Proteomic pathways across the ejection fraction spectrum in patients with heart failure and diabetes mellitus: an EXSCEL trial substudy.Scientific reports · 2025Trial
- Echocardiographic and biomarker characteristics in diabetes, coronary artery disease or both: insights from HOMAGE trial.Cardiovascular diabetology · 2025Trial
- Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction.Scientific reports · 2022Trial
- Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial.Clinical research in cardiology : official journal of the German Cardiac Society · 2021Trial
- Multiomic Profiling in Black and White Populations Reveals Novel Candidate Pathways in Left Ventricular Hypertrophy and Incident Heart Failure Specific to Black Adults.Circulation. Genomic and precision medicine · 2021Trial
- The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.European heart journal · 2021Trial
- Plasma proteomic signatures of social support and their association with cardiovascular disease and mortality: exploratory analyses in a national cohort study.GeroScience · 2026Article
- Proteomic phenotyping with machine learning for cardiovascular outcomes in haemodialysis: insights from the AURORA trial.European heart journal. Digital health · 2026Article
- Takotsubo Syndrome: The First Non-Acute Proteomic Analysis by Remote Dried Blood Microsampling.Journal of cardiovascular translational research · 2026Article
- Large-Scale Proteomic Profiling of Incident Heart Failure and Its Subtypes in Older Adults.Circulation. Genomic and precision medicine · 2026Article
- Lycopene's Role in Mitigating Obesity-Induced Cardiac Remodeling: Insights Into Inflammatory and MMP-2 Pathways.Molecular nutrition & food research · 2026Article
- Causal Associations of Cardiovascular Proteins and Diabetic Nephropathy Revealed by Mediation and Phenome-Wide Mendelian Randomization.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- Proteomic biomarkers and pathway analysis for progression to heart failure in three epidemiological representative cohorts.European journal of heart failure · 2025Article
- Plasma proteomic signatures of social support and their association with cardiovascular disease and mortality.medRxiv : the preprint server for health sciences · 2025Article
- Integrated multiomics of pressure overload in the human heart prioritizes targets relevant to heart failure.Nature communications · 2025Article
- Clinical Insights from Proteomics in Heart Failure.Current heart failure reports · 2025Review
- The chronic heart failure evolutions: Different fates and routes.ESC heart failure · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 10 institutions in 7 countries.
Funding
Abstract
Background Identifying the mechanistic pathways potentially associated with incident heart failure (HF) may provide a basis for novel preventive strategies. Methods and Results To identify proteomic biomarkers and the potential underlying mechanistic pathways that may be associated with incident HF defined as the first hospitalization for HF, a nested-matched case-control design was used with cases (incident HF) and controls (without HF) selected from 3 cohorts (>20 000 individuals). Controls were matched on cohort, follow-up time, age, and sex. Two independent sample sets (a discovery set with 286 cases and 591 controls and a replication set with 276 cases and 280 controls) were used to discover and replicate the findings. Two hundred fifty-two circulating proteins in the plasma were studied. Adjusting for the matching variables age, sex, and follow-up time (and correcting for multiplicity of tests), 89 proteins were found to be associated with incident HF in the discovery phase, of which 38 were also associated with incident HF in the replication phase. These 38 proteins pointed to 4 main network clusters underlying incident HF: (1) inflammation and apoptosis, indicated by the expression of the TNF (tumor necrosis factor)-family members; (2) extracellular matrix remodeling, angiogenesis and growth, indicated by the expression of proteins associated with collagen metabolism, endothelial function, and vascular homeostasis; (3) blood pressure regulation, indicated by the expression of natriuretic peptides and proteins related to the renin-angiotensin-aldosterone system; and (4) metabolism, associated with cholesterol and atherosclerosis. Conclusions Clusters of biomarkers associated with mechanistic pathways leading to HF were identified linking inflammation, apoptosis, vascular function, matrix remodeling, blood pressure control, and metabolism. These findings provide important insight on the pathophysiological mechanisms leading to HF. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02556450.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.